focus -WSS

focus

author：fashion 2025-09-29 22:52:46 - browse：39

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Statins may not be needed by millions of people, study suggests

WSS

Teladoc has a new CEO, but challenges remain the same

How CRISPR works, explained in two minutes

The system is set up to fail children with medical complexity

Failure, not just success, should guide future doctors

St. Louis police protesters begin picking up checks in $4.9 million settlement

Statins may not be needed by millions of people, study suggests

focus

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

How faith leaders like me can help address America's obesity epidemic

Bright Health sells Medicare Advantage business to Molina

California wildfire smoke linked to 52,000 early deaths, study says

Activists slam private health insurers over coverage restrictions

Election results set back Medicaid expansion plans

Sports medicine is finally prioritizing gender equality

Statins may not be needed by millions of people, study suggests

Cancer drug shortages should be causing more outrage

ALS patient reclaims some autonomy thanks to wearable 'robot'

explore

Cheap, fast test for Zika and dengue could cost just $1

Paxlovid rebound happens. Why and to whom are still a mystery

Readers discuss the intersection of pregnancy and addiction

Health care court cases: Humana, Sutter, Novant

How faith leaders like me can help address America's obesity epidemic

Medical device trials still don't enroll enough women, study finds

focus

entertainment

leisure time

entertainment